Panbela Therapeutics Inc
Change company Symbol lookup
Select an option...
PBLA Panbela Therapeutics Inc
SGBXV Safe & Green Holdings Corp
GOOG Alphabet Inc
WHLR Wheeler Real Estate Investment Trust Inc
FRHLF Freehold Royalties Ltd
CTNT Cheetah Net Supply Chain Service Inc
LASE Laser Photonics Corp
GFR M3-Brigade Acquisition III Corp
PCT Purecycle Technologies Inc
UPST Upstart Holdings Inc

Health Care : Biotechnology | Small Cap Value
Company profile

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is involved in enrolling patients in its randomized double-blind placebo-controlled clinical trial for the treatment of pancreatic cancer. The Company's lead assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X). Ivospemin is a polyamine analog designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma and other tumors. Flynpovi is a combination of CPP-1X (eflornithine) and sulindac with a dual mechanism inhibiting polyamine synthesis and increasing polyamine export and catabolism. Eflornithine is being developed as a single-agent tablet or high-dose powder sachet for several indications, including prevention of gastric cancer, treatment of neuroblastoma and recent onset Type 1 diabetes.

Closing Price
Day's Change
-0.07 (-5.34%)
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:
  • Prev Close
  • Today's Open
  • Day's Range
  • Avg Vol (10-day)
  • Last (time)
    3:59p ET 09/22/23
  • Last (size)
  • 52-Wk Range
    1.22 - 636.96
  • (09/26/22 - 09/22/23)
  • 177.1%
  • Market Cap
  • Shares Outstanding
  • -440.85
  • --
  • No dividend
  • Ex-dividend Date
    No dividend
  • Dividend Pay Date
    No dividend
  • 0.8
  • 14.26
  • (% of float 08/31/23)

Latest News

September 19, 2023
8:15 am ET
Globe Newswire
September 05, 2023
8:15 am ET
Globe Newswire
August 28, 2023
8:15 am ET
Globe Newswire
August 14, 2023
8:15 am ET
Globe Newswire
August 10, 2023
4:10 pm ET
Globe Newswire
July 31, 2023
4:15 pm ET
Globe Newswire
July 24, 2023
8:15 am ET
Globe Newswire
July 19, 2023
8:00 am ET
Globe Newswire
July 17, 2023
6:00 am ET
Globe Newswire
July 10, 2023
8:15 am ET
Globe Newswire
June 28, 2023
8:15 am ET
Globe Newswire
June 26, 2023
8:15 am ET
Globe Newswire
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.